Chiara Agrati

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4910062/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nature Communications, 2020, 11, 3410.	5.8	328
2	Unique human immune signature of Ebola virus disease in Guinea. Nature, 2016, 533, 100-104.	13.7	170
3	Cutting Edge: TGF-β1 and IL-15 Induce FOXP3+ γδ Regulatory T Cells in the Presence of Antigen Stimulation. Journal of Immunology, 2009, 183, 3574-3577.	0.4	147
4	Lack of CD27â^'CD45RAâ^'Vγ9VÎ′2+ T Cell Effectors in Immunocompromised Hosts and During Active Pulmonary Tuberculosis. Journal of Immunology, 2002, 168, 1484-1489.	0.4	104
5	In vivo effects of zoledronic acid on peripheral Î ³ δT lymphocytes in early breast cancer patients. Cancer Immunology, Immunotherapy, 2009, 58, 31-38.	2.0	96
6	Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. Cell Death and Disease, 2020, 11, 921.	2.7	96
7	An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019. Clinical Infectious Diseases, 2020, 71, 2272-2275.	2.9	91
8	Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. Journal of Antimicrobial Chemotherapy, 2020, 75, 2977-2980.	1.3	90
9	Antiviral reactivities of $\hat{I}^{3}\hat{I}^{T}$ cells. Microbes and Infection, 2005, 7, 518-528.	1.0	84
10	Cross-subtype Immunity against Avian Influenza in Persons Recently Vaccinated for Influenza. Emerging Infectious Diseases, 2008, 14, 121-128.	2.0	81
11	Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count. Clinical Infectious Diseases, 2022, 75, e552-e563.	2.9	79
12	Anti–Severe Acute Respiratory Syndrome Coronavirus Immune Responses: The Role Played by Vγ9Vδ2 T Cells. Journal of Infectious Diseases, 2006, 193, 1244-1249.	1.9	78
13	Activation of Vγ9VÎ′2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication. International Immunology, 2006, 18, 11-18.	1.8	56
14	Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vγ9VÎ′2 T cells. Aids, 2009, 23, 555-565.	1.0	55
15	Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. Microorganisms, 2021, 9, 1315.	1.6	54
16	Vδ1T Lymphocytes Expressing a Th1 Phenotype Are the Major γδ T Cell Subset Infiltrating the Liver of HCV-infected Persons. Molecular Medicine, 2001, 7, 11-19.	1.9	50
17	Association of Profoundly Impaired Immune Competence in H1N1vâ€Infected Patients with a Severe or Fatal Clinical Course. Journal of Infectious Diseases, 2010, 202, 681-689.	1.9	50
18	In HIV-positive patients, myeloid-derived suppressor cells induce T-cell anergy by suppressing CD3ζ expression through ELF-1 inhibition. Aids, 2015, 29, 2397-2407.	1.0	48

#	Article	IF	CITATIONS
19	Acute Human Immunodeficiency Virus Replication Causes a Rapid and Persistent Impairment of Vγ9VÎ′2 T Cells in Chronically Infected Patients Undergoing Structured Treatment Interruption. Journal of Infectious Diseases, 2002, 186, 847-850.	1.9	46
20	Different features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infections. PLoS Neglected Tropical Diseases, 2017, 11, e0005645.	1.3	46
21	Innate gamma/delta T-cells during HIV infection: Terra relatively Incognita in novel vaccination strategies?. AIDS Reviews, 2011, 13, 3-12.	0.5	42
22	Steatosis and intrahepatic lymphocyte recruitment in hepatitis C virus transgenic mice. Journal of General Virology, 2004, 85, 1509-1520.	1.3	41
23	Coordinate induction of IFN-α and -γ by SARS-CoV also in the absence of virus replication. Virology, 2005, 341, 163-169.	1.1	40
24	COVIDâ€19 in people living with HIV: Clinical implications of dynamics of the immune response to SARSâ€CoVâ€2. Journal of Medical Virology, 2021, 93, 1796-1804.	2.5	38
25	Coordinated cellular and humoral immune responses after twoâ€dose SARS oV2 mRNA vaccination in liver transplant recipients. Liver International, 2022, 42, 180-186.	1.9	36
26	Vγ9Vδ2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy. Immunology Letters, 2005, 100, 14-20.	1.1	35
27	Activated Vγ9Vδ2 T Cells Trigger Granulocyte Functions via MCP-2 Release. Journal of Immunology, 2009, 182, 522-529.	0.4	35
28	Human Zika infection induces a reduction of IFN-Î ³ producing CD4 T-cells and a parallel expansion of effector Vδ2 T-cells. Scientific Reports, 2017, 7, 6313.	1.6	35
29	Hepatitis C virus directâ€acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. Liver International, 2018, 38, 1741-1750.	1.9	35
30	Myeloid-Derived Suppressor Cells Specifically Suppress IFN-Î ³ Production and Antitumor Cytotoxic Activity of Vδ2 T Cells. Frontiers in Immunology, 2018, 9, 1271.	2.2	35
31	UPLC–MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (CS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1073, 183-190.	1.2	34
32	Î ³ Î T Cell Activation by Chronic HIV Infection May Contribute to Intrahepatic VδI Compartmentalization and Hepatitis C Virus Disease Progression Independent of Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2001, 17, 1357-1363.	0.5	31
33	Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption. Aids, 2002, 16, 2431-2438.	1.0	29
34	Multicompartment vectors as novel drug delivery systems: selective activation of Tγδ lymphocytes after zoledronic acid delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 153-161.	1.7	28
35	ZIKV Infection Induces an Inflammatory Response but Fails to Activate Types I, II, and III IFN Response in Human PBMC. Mediators of Inflammation, 2018, 2018, 1-6.	1.4	28
36	Expression of muscarinic m2 receptor mRNA in dorsal root ganglia of neonatal rat. Brain Research, 1999, 824, 63-70.	1.1	25

#	Article	IF	CITATIONS
37	Highly Active Antiretroviral Therapy Restores CD4+ V?? T-Cell Repertoire in Patients With Primary Acute HIV Infection But Not in Treatment-Naive HIV+ Patients With Severe Chronic Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 213-222.	0.9	25
38	Granulocytic Myeloid–Derived Suppressor Cells Increased in Early Phases of Primary HIV Infection Depending on TRAIL Plasma Level. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 575-582.	0.9	25
39	Interferon-α Improves Phosphoantigen-Induced Vγ9VÎ′2 T-Cells Interferon-γ Production during Chronic HCV Infection. PLoS ONE, 2012, 7, e37014.	1.1	23
40	Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. Clinical Infectious Diseases, 2023, 76, e426-e438.	2.9	23
41	Measles Cases during Ebola Outbreak, West Africa, 2013–2106. Emerging Infectious Diseases, 2017, 23, 1035-1037.	2.0	21
42	Accumulation of dysfunctional effector CD8+T cells in the liver of patients with chronic HCV infection. Journal of Hepatology, 2006, 44, 475-483.	1.8	20
43	In HIV/HCV co-infected patients T regulatory and myeloid-derived suppressor cells persist after successful treatment with directly acting antivirals. Journal of Hepatology, 2017, 67, 422-424.	1.8	20
44	Administration of PLP139–151 Primes T Cells Distinct from Those Spontaneously Responsive In Vitro to This Antigen. Journal of Immunology, 2008, 180, 6611-6622.	0.4	19
45	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. Science Translational Medicine, 2022, 14, eabj1996.	5.8	18
46	Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19. Npj Vaccines, 2021, 6, 131.	2.9	18
47	Primary and Chronic HIV Infection Differently Modulates Mucosal Vδ1 and Vδ2 T-Cells Differentiation Profile and Effector Functions. PLoS ONE, 2015, 10, e0129771.	1.1	17
48	Bone Marrow CD34 ⁺ Progenitor Cells from HIV-Infected Patients Show an Impaired T Cell Differentiation Potential Related to Proinflammatory Cytokines. AIDS Research and Human Retroviruses, 2017, 33, 590-596.	0.5	17
49	Murine hepatocyte cell lines promote expansion and differentiation of NK cells from stem cell precursors. Hepatology, 2004, 39, 1508-1516.	3.6	15
50	Non-Pathogenic Mycobacterium smegmatis Induces the Differentiation of Human Monocytes Directly into Fully Mature Dendritic Cells. Journal of Clinical Immunology, 2005, 25, 365-375.	2.0	15
51	Myeloid Derived Suppressor Cells Expansion Persists After Early ART and May Affect CD4 T Cell Recovery. Frontiers in Immunology, 2019, 10, 1886.	2.2	15
52	NaÃ ⁻ ve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study. PLoS ONE, 2019, 14, e0225415.	1.1	15
53	Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response. Journal of Hepatology, 2021, 75, 1301-1311.	1.8	15
54	Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1967-73.	1.4	14

#	Article	IF	CITATIONS
55	Interferonâ€Î³â€"Mediated Antiviral Immunity against Orthopoxvirus Infection Is Provided by γδT Cells. Journal of Infectious Diseases, 2006, 193, 1606-1607.	1.9	13
56	Cellular and Humoral Immune Responses to Pandemic Influenza Vaccine in Healthy and in Highly Active Antiretroviral Therapy-Treated HIV Patients. AIDS Research and Human Retroviruses, 2012, 28, 1606-1616.	0.5	12
57	HIV-Specific CD8 T Cells Producing CCL-4 Are Associated With Worse Immune Reconstitution During Chronic Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 338-344.	0.9	12
58	Impact of ART on dynamics of growth factors and cytokines in primary HIV infection. Cytokine, 2020, 125, 154839.	1.4	12
59	HIV Infection of Monocytes-Derived Dendritic Cells Inhibits Vγ9Vδ2 T Cells Functions. PLoS ONE, 2014, 9, e111095.	1.1	12
60	Brain localization of Kaposi's sarcoma in a patient treated by combination antiretroviral therapy. BMC Infectious Diseases, 2013, 13, 600.	1.3	11
61	Vγ9Vδ2 T-Cell Polyfunctionality Is Differently Modulated in HAART-Treated HIV Patients according to CD4 T-Cell Count. PLoS ONE, 2015, 10, e0132291.	1.1	10
62	Vδ2 T-Cells Kill ZIKV-Infected Cells by NKG2D-Mediated Cytotoxicity. Microorganisms, 2019, 7, 350.	1.6	9
63	Modulation of cholinergic marker expression by nerve growth factor in dorsal root ganglia. Journal of Neuroscience Research, 2000, 62, 591-599.	1.3	8
64	CD3ζ Downâ€Modulation May Explain Vγ9VÎ″2 T Lymphocyte Anergy in HIVâ€Infected Patients. Journal of Infectious Diseases, 2009, 199, 432-436.	1.9	8
65	<i>In Vivo</i> Interferon-Alpha/Ribavirin Treatment Modulates Vγ9Vδ2 T-Cell Function During Chronic HCV Infection. Journal of Interferon and Cytokine Research, 2013, 33, 136-141.	0.5	8
66	IL-18 and Stem Cell Factor affect hematopoietic progenitor cells in HIV-infected patients treated during primary HIV infection. Cytokine, 2018, 103, 34-37.	1.4	8
67	Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for NaÃ ⁻ ve/Memory T Cell Immunomonitoring. Journal of Immunology Research, 2020, 2020, 1-15.	0.9	8
68	Myocarditis-associated necrotizing coronary vasculitis: incidence, cause, and outcome. European Heart Journal, 2021, 42, 1609-1617.	1.0	8
69	Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH. Journal of Clinical Medicine, 2022, 11, 1546.	1.0	8
70	Chronic HIV-Infected Patients Show an Impaired Dendritic Cells Differentiation of Bone Marrow CD34+ Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 342-344.	0.9	7
71	A new procedure to analyze polymorphonuclear myeloid derived suppressor cells in cryopreserved samples cells by flow cytometry. PLoS ONE, 2018, 13, e0202920.	1.1	7
72	Lymphocyte distribution and intrahepatic compartmentalization during HCV infection: a main role for MHC-unrestricted T cells. Archivum Immunologiae Et Therapiae Experimentalis, 2002, 50, 307-16.	1.0	7

#	Article	IF	CITATIONS
73	The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients. Clinical Immunology, 2011, 138, 178-186.	1.4	6
74	Early ART in primary HIV infection may also preserve lymphopoiesis capability in circulating haematopoietic progenitor cells: a case report. Journal of Antimicrobial Chemotherapy, 2015, 70, 1598-1600.	1.3	6
75	In Human Immunodeficiency Virus primary infection, early combined antiretroviral therapy reduced <i>ĴэĴ´</i> Tâ€cell activation but failed to restore their polyfunctionality. Immunology, 2019, 157, 322-330.	2.0	6
76	Per2 Upregulation in Circulating Hematopoietic Progenitor Cells During Chronic HIV Infection. Frontiers in Cellular and Infection Microbiology, 2020, 10, 362.	1.8	6
77	In Acute Dengue Infection, High TIM-3 Expression May Contribute to the Impairment of IFNÎ ³ Production by Circulating Vδ2 T Cells. Viruses, 2022, 14, 130.	1.5	6
78	P-Glycoprotein Expression by Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients Is Independent from Response to Highly Active Antiretroviral Therapy. Vaccine Journal, 2003, 10, 191-192.	3.2	5
79	Influenza Pandemics, Immune Crossâ€Reactivity, and Pandemic Control Strategies. Journal of Infectious Diseases, 2008, 198, 294-295.	1.9	5
80	Molecular characterization of hepatitis A outbreak in the province of Rome, Lazio region, Italy, January–July 2013. Microbes and Infection, 2014, 16, 362-366.	1.0	5
81	Cellular and Humoral Cross-Immunity against Two H3N2v Influenza Strains in Presumably Unexposed Healthy and HIV-Infected Subjects. PLoS ONE, 2014, 9, e105651.	1.1	5
82	Unexpected human cases of cutaneous anthrax in Latium region, Italy, August 2017: integrated human–animal investigation of epidemiological, clinical, microbiological and ecological factors. Eurosurveillance, 2019, 24, .	3.9	5
83	Antiviral activity of human VÎ2 T-cells against WNV includes both cytolytic and non-cytolytic mechanisms. New Microbiologica, 2016, 39, 139-42.	0.1	5
84	Influence of GB Virus Type C and HIV Coinfection on ÂÂ T cells. Clinical Infectious Diseases, 2005, 40, 326-328.	2.9	4
85	Do human $\hat{I}^{3}\hat{I}^{\prime}$ T cells respond to M tuberculosis protein antigens?. Blood, 2008, 112, 4776-4777.	0.6	4
86	In HIV-infected patients, some differential alterations of CD4 and CD8 T cell homeostasis may not be restored by >=7 years of highly active antiretroviral therapy, in spite of good CD4 T cell repopulation. Journal of Antimicrobial Chemotherapy, 2012, 67, 1802-1804.	1.3	4
87	The Different Roles of Interleukin 7 and Interleukin 18 in Affecting Lymphoid Hematopoietic Progenitor Cells and CD4 Homeostasis in Naive Primary and Chronic HIV-Infected Patients. Clinical Infectious Diseases, 2016, 63, 1683-1684.	2.9	3
88	Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis. European Journal of Clinical Pharmacology, 2021, 77, 1583-1585.	0.8	3
89	The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates regulatory/inflammatory signals. IScience, 2022, 25, 103854.	1.9	3
90	Use of Pembrolizumab for Treatment of Progressive Multifocal Leukoencephalopathy in People Living with HIV. Viruses, 2022, 14, 970.	1.5	3

#	Article	IF	CITATIONS
91	Î ³ δT Cells in Emerging Viral Infection: An Overview. Viruses, 2022, 14, 1166.	1.5	3
92	Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects. Journal of Antimicrobial Chemotherapy, 2022, 77, 2683-2687.	1.3	3
93	Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. Journal of Antimicrobial Chemotherapy, 2018, 73, 160-164.	1.3	2
94	Unawareness of HCV serostatus among persons newly diagnosed with HIV. Journal of Infection and Public Health, 2019, 12, 733-737.	1.9	2
95	Persistent gamma delta Tâ€cell dysfunction in HCV/HIV coâ€infection despite directâ€acting antiviral therapyâ€induced cure. Journal of Viral Hepatitis, 2020, 27, 754-756.	1.0	2
96	Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia. Scientific Reports, 2021, 11, 11334.	1.6	2
97	Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. Nutrients, 2021, 13, 3571.	1.7	2
98	The importance of advanced cytometry in defining new immune cell types and functions relevant for the immunopathogenesis of HIV infection. Aids, 2020, 34, 2169-2185.	1.0	2
99	Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection. Pharmaceuticals, 2022, 15, 403.	1.7	2
100	Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients. Clinical Immunology, 2017, 183, 82-90.	1.4	0
101	GB virus type C crossâ€reactivity in clinical samples with a low hepatitis C virus antibody positive response. Apmis, 2019, 127, 109-111.	0.9	0
102	Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 135-142.	0.6	0